DexCom Statistics
Total Valuation
DexCom has a market cap or net worth of $26.58 billion. The enterprise value is $26.23 billion.
| Market Cap | 26.58B |
| Enterprise Value | 26.23B |
Important Dates
The next confirmed earnings date is Thursday, October 30, 2025, after market close.
| Earnings Date | Oct 30, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
DexCom has 392.16 million shares outstanding. The number of shares has decreased by -2.97% in one year.
| Current Share Class | 392.16M |
| Shares Outstanding | 392.16M |
| Shares Change (YoY) | -2.97% |
| Shares Change (QoQ) | +0.17% |
| Owned by Insiders (%) | 0.31% |
| Owned by Institutions (%) | 94.41% |
| Float | 389.53M |
Valuation Ratios
The trailing PE ratio is 47.39 and the forward PE ratio is 28.91. DexCom's PEG ratio is 1.23.
| PE Ratio | 47.39 |
| Forward PE | 28.91 |
| PS Ratio | 6.18 |
| Forward PS | 5.24 |
| PB Ratio | 10.33 |
| P/TBV Ratio | 10.80 |
| P/FCF Ratio | 46.57 |
| P/OCF Ratio | 26.91 |
| PEG Ratio | 1.23 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 28.41, with an EV/FCF ratio of 45.95.
| EV / Earnings | 45.90 |
| EV / Sales | 6.10 |
| EV / EBITDA | 28.41 |
| EV / EBIT | 38.17 |
| EV / FCF | 45.95 |
Financial Position
The company has a current ratio of 1.52, with a Debt / Equity ratio of 1.00.
| Current Ratio | 1.52 |
| Quick Ratio | 1.30 |
| Debt / Equity | 1.00 |
| Debt / EBITDA | 2.69 |
| Debt / FCF | 4.52 |
| Interest Coverage | 36.17 |
Financial Efficiency
Return on equity (ROE) is 22.83% and return on invested capital (ROIC) is 8.44%.
| Return on Equity (ROE) | 22.83% |
| Return on Assets (ROA) | 6.08% |
| Return on Invested Capital (ROIC) | 8.44% |
| Return on Capital Employed (ROCE) | 17.10% |
| Revenue Per Employee | $417,553 |
| Profits Per Employee | $55,485 |
| Employee Count | 10,300 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 3.05 |
Taxes
In the past 12 months, DexCom has paid $212.60 million in taxes.
| Income Tax | 212.60M |
| Effective Tax Rate | 27.11% |
Stock Price Statistics
The stock price has decreased by -1.22% in the last 52 weeks. The beta is 1.48, so DexCom's price volatility has been higher than the market average.
| Beta (5Y) | 1.48 |
| 52-Week Price Change | -1.22% |
| 50-Day Moving Average | 75.23 |
| 200-Day Moving Average | 79.26 |
| Relative Strength Index (RSI) | 39.73 |
| Average Volume (20 Days) | 6,780,736 |
Short Selling Information
The latest short interest is 13.14 million, so 3.35% of the outstanding shares have been sold short.
| Short Interest | 13.14M |
| Short Previous Month | 11.10M |
| Short % of Shares Out | 3.35% |
| Short % of Float | 3.37% |
| Short Ratio (days to cover) | 3.18 |
Income Statement
In the last 12 months, DexCom had revenue of $4.30 billion and earned $571.50 million in profits. Earnings per share was $1.43.
| Revenue | 4.30B |
| Gross Profit | 2.53B |
| Operating Income | 687.20M |
| Pretax Income | 784.10M |
| Net Income | 571.50M |
| EBITDA | 923.30M |
| EBIT | 687.20M |
| Earnings Per Share (EPS) | $1.43 |
Balance Sheet
The company has $2.93 billion in cash and $2.58 billion in debt, giving a net cash position of $350.00 million or $0.89 per share.
| Cash & Cash Equivalents | 2.93B |
| Total Debt | 2.58B |
| Net Cash | 350.00M |
| Net Cash Per Share | $0.89 |
| Equity (Book Value) | 2.57B |
| Book Value Per Share | 6.56 |
| Working Capital | 1.72B |
Cash Flow
In the last 12 months, operating cash flow was $987.70 million and capital expenditures -$416.90 million, giving a free cash flow of $570.80 million.
| Operating Cash Flow | 987.70M |
| Capital Expenditures | -416.90M |
| Free Cash Flow | 570.80M |
| FCF Per Share | $1.46 |
Margins
Gross margin is 58.77%, with operating and profit margins of 15.98% and 13.29%.
| Gross Margin | 58.77% |
| Operating Margin | 15.98% |
| Pretax Margin | 18.23% |
| Profit Margin | 13.29% |
| EBITDA Margin | 21.47% |
| EBIT Margin | 15.98% |
| FCF Margin | 13.27% |
Dividends & Yields
DexCom does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 2.97% |
| Shareholder Yield | 2.97% |
| Earnings Yield | 2.15% |
| FCF Yield | 2.15% |
Analyst Forecast
The average price target for DexCom is $97.42, which is 43.73% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $97.42 |
| Price Target Difference | 43.73% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 19 |
| Revenue Growth Forecast (5Y) | 14.30% |
| EPS Growth Forecast (5Y) | 26.26% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on June 13, 2022. It was a forward split with a ratio of 4:1.
| Last Split Date | Jun 13, 2022 |
| Split Type | Forward |
| Split Ratio | 4:1 |
Scores
DexCom has an Altman Z-Score of 5.47 and a Piotroski F-Score of 6.
| Altman Z-Score | 5.47 |
| Piotroski F-Score | 6 |